SHR-1701 + paclitaxel + cisplatin + carboplatin

SHR-1701 + paclitaxel + cisplatin + carboplatin is a combination regimen under investigation primarily for neoadjuvant treatment of locally advanced, resectable esophageal squamous cell carcinoma (ESCC). SHR-1701 is a bifunctional fusion protein combining a monoclonal antibody against programmed death-ligand 1 (PD-L1) with the extracellular domain of transforming growth factor beta receptor II (TGF-βRII), enabling dual blockade of PD-L1 and TGF-β signaling to enhance anti-tumor immunity. Paclitaxel is a taxane cytotoxic agent stabilizing microtubules and inhibiting mitosis. Cisplatin and carboplatin are platinum-based chemotherapeutics causing DNA crosslinking and apoptosis. In this regimen, these agents are given together to augment antitumor activity before surgical resection. The combination has been evaluated in phase II trials for resectable ESCC, showing promising pathological complete response rates and acceptable toxicity. The component drugs have also established efficacy in other cancers, including ovarian, cervical, lung, and head and neck cancers[1][2][3][4][6].